论文部分内容阅读
目的探讨手术后同步放化疗对脑胶质瘤患者预后的影响,为改善患者的预后提供临床依据。方法选取2009年8月至2010年8月间收治的72例脑胶质瘤患者,按照随机数字表分为观察组和对照组,每组36例,均于外院接受脑胶质瘤手术后于我院接受放射治疗,观察组患者在此基础上接受化疗,比较两组患者的预后。结果观察组患者总有效率为77.8%,对照组患者总有效率为47.2%,两组比较差异有统计学意义(P<0.05)。观察组患者眼痛发生率高于对照组,差异有统计学意义(P<0.05);观察组患者骨髓抑制、恶心呕吐、发热及血常规变化发生率均低于对照组,差异均有统计学意义(均P<0.05);两组患者癫痫发生率差异无统计学意义(P>0.05)。两组患者治疗1年后肿瘤残余体积均显著降低,观察组肿瘤缩小率为73.9%,对照组为41.8%,两组比较差异有统计学意义(P<0.05)。观察组与对照组患者3年生存率分别为52.8%和16.7%,两组比较差异有统计学意义(P<0.05)。结论手术后同步放化疗可使脑胶质瘤患者生存预期得到有效改善,全身不良反应可耐受,有利于患者长期治疗,值得临床广泛推广。
Objective To investigate the effect of concurrent chemoradiotherapy on the prognosis of patients with glioma and to provide a clinical basis for improving the prognosis of patients. Methods Totally 72 patients with glioma who were admitted between August 2009 and August 2010 were divided into observation group and control group according to the random number table. Each group had 36 patients with glioma, Radiotherapy was performed in our hospital. Patients in the observation group received chemotherapy on this basis and the prognosis was compared between the two groups. Results The total effective rate was 77.8% in the observation group and 47.2% in the control group. There was significant difference between the two groups (P <0.05). The incidence of eye pain in the observation group was higher than that in the control group (P <0.05). The incidences of myelosuppression, nausea and vomiting, fever and blood tests in the observation group were lower than those in the control group, with statistical differences (P <0.05). There was no significant difference in the incidence of epilepsy between the two groups (P> 0.05). After 1 year of treatment, tumor residual volume was significantly decreased in both groups. The tumor shrinkage rate was 73.9% in the observation group and 41.8% in the control group. The difference between the two groups was statistically significant (P <0.05). The 3-year survival rates of observation group and control group were 52.8% and 16.7% respectively, with significant difference between the two groups (P <0.05). Conclusions Simultaneous chemoradiotherapy after operation can effectively improve the survival of patients with glioma, systemic adverse reactions can be tolerated, is conducive to long-term treatment of patients, it is worth widely clinical promotion.